Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96IP4

UPID:
TET5A_HUMAN

ALTERNATIVE NAMES:
HBV X-transactivated gene 11 protein; HBV XAg-transactivated protein 11

ALTERNATIVE UPACC:
Q96IP4; A8K7U4; Q5TF86; Q8NFZ9; Q9BW32; Q9NXV5

BACKGROUND:
The protein Terminal nucleotidyltransferase 5A, with alternative names HBV X-transactivated gene 11 protein and HBV XAg-transactivated protein 11, is pivotal in the cytoplasmic polyadenylation process. It specifically targets mRNA related to extracellular matrix and bone mineralization, playing a significant role in osteoblast mineralization.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in bone mineralization and its association with Osteogenesis imperfecta 18, a condition marked by bone fragility and susceptibility to fractures, Terminal nucleotidyltransferase 5A represents a promising target for developing new treatments for bone disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.